Autopsy report · NCT05990478

A Study of Contrast-Enhanced Mammography (CEM) Scans in People With Breast Cancer

“Challenges to participant accrual”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Sponsor

Memorial Sloan Kettering Cancer Center

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Contrast-Enhanced Mammography; Breast MRI

Participants

0

Trials that died the same way

• Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
  “lack of participant accrual” (83% match in meaning)
• Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls"
  “Accrual difficulties” (77% match in meaning)
• 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
  “Low participant accrual” (77% match in meaning)
• A Prospective Pilot Study for the Evaluation of 18F- Fluciclovine PET/MRI in Radio-recurrent Prostate Cancer (RRPC-PET/MRI Study)
  “0 participant accrual” (71% match in meaning)
• Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
  “lack of accrual” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.